Adlai Nortye dives in Nasdaq debut, as key product faces hurdles
Shares of the drug maker that licenses its products from other companies lost more than half their value in the two weeks after their listing Key Takeaways: Newly listed Adlai…
Recent Articles
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK -
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
